Skip to content
You can now search across every topic, entity and event.What's new
UK Startups and Innovation
24AUG

Moa raises £22.2m to outrun resistance

3 min read
16:40UTC

Moa Technology, an Oxford Plant Sciences spinout, closed a £22.2m Series C on 23 July after screening more than 900,000 compounds for herbicides that weeds have not yet defeated.

TechnologyDeveloping
Key takeaway

New herbicide chemistry from Oxford reaches farmers through four incumbent agrochemical companies, not through Moa.

Moa Technology, an Oxford Plant Sciences spinout from 2017, closed a £22.2 million Series C on Thursday 23 July co-led by Oxford Science Enterprises and Supernova Invest 1. The company has screened more than 900,000 compounds and found over 80 novel herbicide modes of action. Magdalen College Oxford joined the round alongside GrainInnovate, the Agri Investment Fund and Infinity Investment Partners 2.

A mode of action is the biochemical route by which a chemical kills a plant. Commercial herbicides have leaned on a handful of those routes for decades, weeds have evolved around them, and growers in Australia and the American Midwest are running short of chemistry that still works. Finding a genuinely new route is rare enough that agrochemical majors have gone years without one.

Moa Technology has built no sales force to carry those 80 routes to a field. Its research partnerships run through four incumbent agrochemical companies that already own the distribution and the regulatory teams: Nufarm, Gowan, Certis Belchim and Corteva Agriscience. Moa's chemistry therefore reaches a field on somebody else's sales ledger. Commercialisation is routed through industry here as it is at Humanoid, though this buys a path to market rather than a factory, and none of it is equity.

University spinout deals fell 33% by count last year . A 2017 vintage closing a Series C with Parkwalk and Oxford University Innovation still on the register is what the surviving tail of that pipeline looks like. Agricultural chemistry runs on decade-long timelines: regulatory approval for a new active ingredient takes years after the Science is settled, which is why the survivors are old and the count is falling.

Deep Analysis

In plain English

Moa Technology is a company that grew out of Oxford University's plant science department. Weeds on farms are increasingly resistant to the herbicides farmers already use, in the same way bacteria can become resistant to antibiotics. Moa built software that tests hundreds of thousands of chemical compounds to find new ways to kill resistant weeds that current products cannot. It raised £22.2m to keep developing these, and several big agricultural chemical companies are already working with it to test the most promising candidates.

Deep Analysis
Root Causes

Herbicide resistance evolves because repeated use of the same mode of action selects for the small fraction of a weed population that already carries a resistance mutation; with only a handful of commercial modes of action in wide global use, farmers have had no rotation option broad enough to break that selection pressure, which is the specific gap over 80 new modes of action would need to fill rather than merely adding another product using an existing mechanism.

Discovery of new modes of action stalled industry-wide because large agrochemical companies scaled back internal discovery chemistry after patent cliffs on glyphosate and other blockbusters reduced R&D budgets in the 2000s and 2010s, leaving a gap that a machine-learning screening specialist like Moa, spun out of Oxford Plant Sciences, could enter with lower fixed costs than an incumbent rebuilding a wet-lab discovery programme from scratch.

What could happen next?
  • Opportunity

    A confirmed new mode of action would give UK and global farmers their first genuinely new resistance-management tool in decades, extending the useful life of existing herbicides by allowing rotation.

  • Risk

    None of the 80-plus modes of action Moa reports finding in screening has yet been confirmed in field trials or regulatory filings, so the commercial number that matters, how many reach an approved product, remains unknown.

First Reported In

Update #13 · Humanoid hit $1.35bn on a customer order

PR Newswire· 31 Jul 2026
Read original
Causes and effects
This Event
Moa raises £22.2m to outrun resistance
Moa has found new chemistry but built no sales force, so its route to a field runs through four incumbent agrochemical companies that already own the distribution.
Different Perspectives
Highland Europe
Highland Europe
Highland Europe, the growth-equity firm behind a €1bn-plus fund, took €65m from the British Business Bank into its Technology Growth Fund VI on 30 July via British Patient Capital. For a Geneva-based growth investor, the Bank's cheque is routine cornerstone capital, unrelated to which Whitehall department currently claims to sponsor UKRI.
Integrity Growth Partners
Integrity Growth Partners
The Los Angeles firm put £16.1m into Prevalent AI on 24 August, the London GCHQ-alumni company's first outside capital, specifically to fund its US expansion. Its stake is a single commercial bet on one UK deep-tech founder's American growth, not a comment on which department UKRI answers to this month.
Temasek
Temasek
Temasek led PhysicsX's Series C on 30 July, into which the British Business Bank put $25m through British Growth Partnership Fund I. State-backed pension capital rides behind a foreign-led growth round while UK weekly tech funding fell 72% to £102.95m across nine rounds three weeks later.
Innovate UK's Women in Innovation cohort
Innovate UK's Women in Innovation cohort
Sixty-one founders won £75,000 grants from Innovate UK on 5 August, the programme's largest-ever cohort, with a further 39 highly commended founders taking support without cash. For these founders the sponsorship dispute over UKRI's parent department is academic: the money and mentoring arrived exactly as scheduled.
Financial Conduct Authority
Financial Conduct Authority
The FCA added five fintechs, ClearScore, Modulr, Teya, Urban Jungle and Zilch, to its Scale-up Unit on 7 August, the first cohort it regulates solely rather than jointly with the Prudential Regulation Authority. The unit's expansion is a routine regulatory build-out running on its own timetable, unconnected to the sponsorship dispute over its sister department UKRI.
Cabinet Office
Cabinet Office
The Cabinet Office ran the DSIT-to-BIST transfer as a standard cross-government machinery change, the kind gov.uk pages and framework documents routinely take months to catch up with after any department is abolished or renamed. Officials treat the paperwork lag as administrative sequencing, not dysfunction: funding and grant-approval layers moved first because they had to keep working.